5 Key Takeaways
-
1
The Phase 1b trial of ASP7317 demonstrated a favorable safety profile with no significant adverse effects reported.
-
2
Best-corrected visual acuity improved in small and medium cohorts over 52 weeks compared to the fellow eye.
-
3
Geographic atrophy area showed stabilization over time during the study.
-
4
Most patients reported that their vision was either the same or improved according to the Patient Global Impression of Change questionnaire.
-
5
ASP7317 is a human stem cell-derived retinal pigment epithelial cell therapy for advanced geographic atrophy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.